Familial Mediterranean fever, Inflammation and Nephrotic Syndrome: Fibrillary Glomerulopathy and the M680I Missense Mutation
© Fisher et al; licensee BioMed Central Ltd. 2003
Received: 31 March 2003
Accepted: 11 August 2003
Published: 11 August 2003
Familial Mediterranean fever (FMF) is an autosomal recessive disease characterized by inflammatory serositis (fever, peritonitis, synovitis and pleuritis). The gene locus responsible for FMF was identified in 1992 and localized to the short arm of chromosome 16. In 1997, a specific FMF gene locus, MEFV, was discovered to encode for a protein, pyrin that mediates inflammation. To date, more than forty missense mutations are known to exist. The diversity of mutations identified has provided insight into the variability of clinical presentation and disease progression.
We report an individual heterozygous for the M680I gene mutation with a clinical diagnosis of FMF using the Tel-Hashomer criteria. Subsequently, the patient developed nephrotic syndrome with biopsy-confirmed fibrillary glomerulonephritis (FGN). Further diagnostic studies were unremarkable with clinical workup negative for amyloidosis or other secondary causes of nephrotic syndrome.
Individuals with FMF are at greater risk for developing nephrotic syndrome. The most serious etiology is amyloidosis (AA variant) with renal involvement, ultimately progressing to end-stage renal disease. Other known renal diseases in the FMF population include IgA nephropathy, IgM nephropathy, Henoch-Schönlein purpura as well as polyarteritis nodosa.
To our knowledge, this is the first association between FMF and the M680I mutation later complicated by nephrotic syndrome and fibrillary glomerulonephritis.
Familial Mediterranean Fever (FMF) is an autosomal recessive disease primarily affecting individuals of Armenian, Turkish, Arab, and Jewish origin . The disease is characterized by recurrent episodes of fever, pleuritis, peritonitis, synovitis, and pericarditis [2–4]. The most serious complication of FMF is the development of amyloidosis (AA variant), leading to nephrotic syndrome and end-stage renal disease . Amyloidosis remains the leading cause of FMF-related mortality in affected individuals not receiving colchicine prophylaxis . Additionally, other non-amyloid renal diseases are reported to occur in the FMF population with variable prevalence; for example, IgA and IgM nephropathy, and vasculitides including both polyarteritis nodosa (PAN) and Henoch-Schonlëin purpura . Differentiation of the underlying renal disease in FMF patients who present with nephrotic syndrome is difficult, often requiring further diagnostic studies to identify the etiology. Moreover, the identification of the etiology of nephrotic syndrome is critical in determining an effective treatment regimen. For example, patients with amyloidosis (AA variant) usually respond to oral colchicine, which is known to prevent the insidious onset of end-stage renal disease . In contrast, patients with PAN or Henoch-Schonlëin purpura usually respond very well to corticosteroids, with some experiencing complete resolution of proteinuria. 
In 1992, the gene responsible for Familial Mediterranean Fever (FMF), MEFV, was found to reside on the short arm of chromosome 16 . Five-years later, the MEFV gene locus was discovered to encode for a protein, pyrin (marenostrin), a member of the RoRet gene family [8, 9]. Pyrin is known to play a role in mitigating an inflammatory response [8, 10]. To date, more than forty missense mutations are noted in association with FMF. One specific mutation, M694V, has been implicated as a risk factor for amyloidosis, especially in North African Jews homozygous for the M694V missense mutation . However, individuals with mutations other than M694V are known to develop amyloidosis with renal involvement . For the first time, we report an individual with symptomatic FMF, heterozygous for the M680I missense mutation, who developed progressive proteinuria, hematuria, and subsequent nephrotic syndrome secondary to fibrillary glomerulonephritis.
A forty-nine year-old American man of Armenian ancestry was diagnosed clinically with Familial Mediterranean Fever (FMF) at age 39. At that time, he presented with recurrent, episodic fevers, peritonitis, synovitis, and pleuritis. Since the initial diagnosis, his treatment consisted of oral colchicine (1.2 mg/day), resulting in a decrease in the frequency, duration, and intensity of his inflammatory episodes. However, over the subsequent decade, his inflammatory episodes became more frequent, occurring every 7–10 days, with an average duration of approximately 3 days. His symptoms consisted of diffuse abdominal pain, sharp, non-radiating chest pain, and fevers as high as 103 degrees F. An extensive workup for other etiologies responsible for febrile illness was unremarkable (e.g. infection, malignancy, connective tissue disorders). Upon further examination, the previous diagnosis of FMF was confirmed using the Tel-Hashomer criteria .
MEFV missense mutations evaluted in our patient
Once regarded simply as an inflammatory, autosomal recessive disease of unknown etiology, the spectrum of FMF has evolved as a complex genetic puzzle during the genomic era. More than forty missense mutations resulting in abnormal pyrin proteins have led to a new paradigm for FMF as an inherited state of dysregulated inflammation. The altered gene products – the so-called pyrins – are fundamental to understanding FMF. Pyrin-containing proteins play a pivotal role in the immune response by serving as key inflammatory mediators. Unsurprisingly, pyrin is found in large quantities in neutrophils and released in response to inflammatory stimuli. Additionally, a recently discovered pyrin-like domain was found to exist at the amino-terminal of several proteins involved in cell-signaling pathways inherent to inflammation. One pyrin protein, belonging to a larger class of the pyrin domain family, is involved in the Nuclear Factor-kappa B (NF-kB) cell-signaling pathway. Nuclear Factor-kappa B is an important transcription factor involved in inflammation via its induction of pro-inflammatory gene products. In individuals with the "wild-type" MEFV gene, pyrin serves a key role in regulating the intensity of the inflammatory response. In contrast, individuals with one or more missense mutations at the MEFV locus produce a pyrin protein with altered or absent function. Consequently, the response to inflammation is altered. The resultant dysregulated inflammatory response often times exceeds physiologic parameters and is disproportionate to the insult. [18–22]
The inflammation of FMF may not only be characterized as dysregulated, but is also chronic and recurrent. Its severity and duration have been associated with the secondary development of amyloidosis (AA variety). The amyloid fibrils that lead to nephrotic syndrome in FMF are derived from a serum precursor, serum amyloid A (SAA), itself the result of chronic inflammation. Amyloidosis, with renal involvement and nephrotic syndrome, has become the expected complication of long-term FMF. [14–17]
The novel association between FMF and fibrillary glomerulopathy in this patient raises two contingent questions. First, is the association itself a chance one, but if it is not, is fibrillary glomerulopathy like amyloidosis the result of material deposition that reflects chronic, dysregulated inflammatory activity? The present state of knowledge regarding fibrillary glomerular diseases strongly suggests that the presence of fibrils in the glomeruli of affected individuals represents fibrillar derivation from circulating immunologic molecules, fragments, or immune complexes . Since their etiology, deposition and structure are analogous to that of amyloid in FMF, it is highly intriguing to postulate that this patient's renal involvement is more than a chance occurrence. Prior disease associations with the fibrillary glomerulopathies involve the presence of immune response-associated products [14, 15]. Future reports of individuals or kindred with FMF, nephrotic syndrome and fibrillary glomerulopathy will be required to substantiate our theory.
Although the association between chronic inflammation and amyloidosis (AA) is well known, the present description of fibrillary glomerulopathy in FMF requires further elucidation. Nevertheless, the new association among FMF, nephrotic syndrome, fibrillary glomerulopathy, and an M680I (Figure 3) heterozygous genotype may represent a novel renal complication of FMF. Furthermore, it is suggested that symptomatic heterozygous individuals may actually be compound heterozygotes for a mutation not yet identified . As the number of MEFV mutations discovered continues to increase, more data will become available revealing further relationships among the many different MEFV missense mutations and their phenotypic expression in various ethnic groups.
Written consent was obtained from the patient for publication of the patient's details. I would like to acknowledge this patient for his perseverance, motivation, and unrelenting will to overcome the many obstacles he has and will encounter in the future.
I would also like to acknowledge the following physicians:
Dr. Gabriel Berlin†
Director, Outpatient Clinic for Adults and Children, Evanston Northwestern Healthcare, Evanston, IL
†For his clinical wisdom and dedication to the care of this patient.
‡Mark Haas, MD, PhD
Associate Professor of Pathology, Director, Electron Microscopy Laboratory The Johns Hopkins University School of Medicine, Baltimore, MD
‡For his expert analysis of the renal biopsy specimens and confirmation of the diagnosis of fibrillary glomerulonephritis.
- Sohar E, Merker HJ, Missmahl HP, Gafni J, Heller H: Electron-microscope observations on peri-reticulin and peri-collagen amyloidosis in rectal biopsies. J Pathol Bacteriol. 1967, 94: 89-93.View ArticlePubMedGoogle Scholar
- Reiman H: Periodic disease. Probable syndrome including periodic fever. JAMA. 1948, 136: 239-244.View ArticleGoogle Scholar
- Matzner Y: Biologic and clinical advances in familial mediterranean fever. Review of Oncology and Hematology. 1995, 18: 197-295. 10.1016/1040-8428(94)00130-L.View ArticleGoogle Scholar
- Shohat M, Magel N, Shohat T, Chen X, Dagan T, Mimouni A, Danon Y, Lotan R, Ogur G, Sirin A, Schlezinger M, Halpern GJ, Schwabe A, Kastner D, Rotter JI, N F-G: Phenotype-genotype correlation in familial Mediterranean fever: evidence for an association between Met694Val and amyloidosis. Eur J Hum Genet. 1999, 3: 287-292. 10.1038/sj.ejhg.5200303.View ArticleGoogle Scholar
- Zemer DPM, Sohar E, Modan M, Cabili S, Gafni J: Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. N Eng J Med. 1986, 314: 1001-1005.View ArticleGoogle Scholar
- Tekin M, Yalcinkaya F, Tumer N, Cakar N, Kocak H, Ozkaya N, Gencgonul H: Familial Mediterranean fever – renal involvement by diseases other than amyloid. Nephrol Dial Transplant. 1999, 14: 475-479. 10.1093/ndt/14.2.475.View ArticlePubMedGoogle Scholar
- Pras EAI, Gruberg L, Balow JE, Prosen L, Dean M, Steinberg AD, Pras M, Kastner DL: Mapping of a gene causing familial Mediterranean fever to the short arm of chromosome 16. N Eng J Med. 1992, 326: 1509-1513.View ArticleGoogle Scholar
- A candidate gene for familial Mediterranean fever. The French FMF Consortium. Nat Genet. 1997, 17: 25-31.
- Ancient missense mutations in a new member of the Ro-Ret gene family are likely to cause familial Mediterranean fever. The International FMF Consortium. Cell. 1997, 90: 797-807.
- Pras M: Familial Mediterranean fever: from clinical syndrome to the cloning of the Pyrin gene. Scand J Rheumatol. 1998, 27: 92-97. 10.1080/030097498440949.View ArticlePubMedGoogle Scholar
- Mimouni A, Magal N, Stoffman N, Shohat T, Minasian A, Krasnov M, Halpern GJ, Rotter JI, Fischel-Ghodsian N, Danon YL, Shohat M: Familial Mediterranean fever: effects of genotype and ethnicity on inflammatory attacks and amyloidosis. Pediatrics. 2000, 105: E70-View ArticlePubMedGoogle Scholar
- Livneh A, Langevitz P, Zemer D, Zaks N, Kees S, Lidar T, Migdal A, Padeh S, Pras M: Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum. 1997, 40: 1879-1885.View ArticlePubMedGoogle Scholar
- Eisenberg S, Aksentijevich I, Deng Z, Kastner DL, Matzner YI: Diagnosis of familial Mediterranean fever by a molecular genetics method. Ann Intern Med. 1998, 129: 539-542.View ArticlePubMedGoogle Scholar
- Schwartz MM, Korbet SM, Lewis EJ: Immunotactoid Glomerulopathy. J Am Soc Nephrol. 2002, 13: 1390-1397.View ArticlePubMedGoogle Scholar
- Korbet S, Schwartz S, Lewis E: The Fibrillary Glomerulopathies. Am J Kidney Dis. 1994, 23: 751-765.View ArticlePubMedGoogle Scholar
- Iskandar SS, Falk RJ, Jennette JC: Clinical and pathologic features of fibrillary glomerulonephritis. Kidney Int. 1992, 42: 1401-1407.View ArticlePubMedGoogle Scholar
- Mitchell A: Cell signalling: pyrin fever. Nat Rev Mol Cell Biol. 2002, 3: 150-10.1038/nrm764.View ArticleGoogle Scholar
- Guijarro C, Egido J: Transcription factor-Kappa B (Nf-Kappa B) and renal disease. Kidney Int. 2001, 59: 415-424. 10.1046/j.1523-1755.2001.059002415.x.View ArticlePubMedGoogle Scholar
- Ray A, Ray B: Persistent expression of serum amyloid A during experimentally induced chronic inflammatory condition in rabbit involves differential activation of SAF, Nf-Kappa B, and C/Ebp transcription factors. J Immunol. 1999, 163: 2143-2150.PubMedGoogle Scholar
- Lawrence T, Gilroy GW, Colville-Nash PR, Willoughby D: Possible new role for Nf-Kappa B in the resolution of Inflammation. Nat Med. 2001, 7: 1291-1297. 10.1038/nm1201-1291.View ArticlePubMedGoogle Scholar
- Manji G, Wang L, Geddes B, Brown M, Merriam S, Al-Garawi A, Mak S, Lora J, Briskin M, Jurman M, Cao J, DiStefano P, Bertin J: PYPAF1, a PYRIN-containing Apaf1-like protein that assembles with ASC and regulates activation of NF-Kappa B. J Biol Chem. 2002, 277: 11570-11575. 10.1074/jbc.M112208200.View ArticlePubMedGoogle Scholar
- Livneh A, Langevitz P, Shinar Y, Zaks N, Kastner DL, Pras M, Pras E: MEFV mutation analysis in patients suffering from amyloidosis of familial Mediterranean fever. Amyloid. 1999, 6: 1-6.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2369/4/6/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.